(Q37263371)

19 August 2017

1 reference

title

Novel approaches to imatinib- and sunitinib-resistant GIST. (English)

1 reference

19 August 2017

Peter Reichardt

1

1 reference

19 August 2017

1 July 2008

1 reference

19 August 2017

Current Oncology Reports

1 reference

19 August 2017

10

1 reference

19 August 2017

4

1 reference

19 August 2017

344-349

1 reference

https://scigraph.springernature.com/pub.10.1007/s11912-008-0053-4

19 August 2017

0 references

cites work

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

1 reference

12 December 2020

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

1 reference

12 December 2020

Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants

1 reference

12 December 2020

Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN107 in gastrointestinal stromal tumor cell lines

1 reference

12 December 2020

An update on molecular genetics of gastrointestinal stromal tumours.

1 reference

12 December 2020

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

1 reference

12 December 2020

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

1 reference

12 December 2020

Biology of gastrointestinal stromal tumors.

1 reference

12 December 2020

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

1 reference

12 December 2020

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

1 reference

12 December 2020

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

1 reference

12 December 2020

Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies

1 reference

12 December 2020

Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor.

1 reference

12 December 2020

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

1 reference

12 December 2020

Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate

1 reference

12 December 2020

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

1 reference

12 December 2020

Resistance to c-KIT kinase inhibitors conferred by V654A mutation

1 reference

12 December 2020

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

1 reference

12 December 2020

Flavopiridol targets c-KIT transcription and induces apoptosis in gastrointestinal stromal tumor cells.

1 reference

12 December 2020

10.1007/S11912-008-0053-4

Identifiers

DOI

1 reference

19 August 2017

1 reference

PubMed ID

18778561